Integrated database construction of genomic information and clinical information obtained by clinical sequence

Integrated database construction of genomic information and clinical information obtained by clinical sequence - Integrated database construction of genomic information and clinical information obtained by clinical sequence

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034153

Enrollment

100

Registered

2018-10-01

Start date

2016-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Malignant diseases for which established clinical diagnosis is confirmed 2) Case in which the written agreement was acquired with the free will of the patient after understanding after receiving sufficient explanation for participation in the research

Exclusion criteria

Exclusion criteria: Cases judged inappropriate by the attending physician.

Design outcomes

Primary

Measure	Time frame
1) Percentage of cases in which clinical sequences were received, with actionable mutation (unapproved for genetic mutation and with matching drugs including investigational drugs) 2) Percentage of patients who selected treatment based on clinical sequence results 3) Treatment outcome of case 2) 4) Frequency of accidental findings and secondary findings 5) In addition, the sequence success rate, the frequency of genetic mutation for all cases, the frequency of genetic mutation in carcinomas, the relationship between sequence results and survival time, etc. are extensively studied.	—

Measure

Time frame

1) Percentage of cases in which clinical sequences were received, with actionable mutation (unapproved for genetic mutation and with matching drugs including investigational drugs) 2) Percentage of patients who selected treatment based on clinical sequence results 3) Treatment outcome of case 2) 4) Frequency of accidental findings and secondary findings 5) In addition, the sequence success rate, the frequency of genetic mutation for all cases, the frequency of genetic mutation in carcinomas, the relationship between sequence results and survival time, etc. are extensively studied.

—

Countries

Japan

Contacts

Public ContactMasayuki Kano

Graduate School of Medicine, Chiba University Department of Frontier Surgery

mkano@chiba-u.jp043-226-2109

Outcome results